Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: Mycophenolate sodium

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 50 mg | $37 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $58 | - | In Stock |
| Description | Mycophenolic acid sodium is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), exhibiting an EC50 value of 0.24 μM. Mycophenolic acid sodium demonstrates broad antiviral activity against RNA viruses, including influenza. Mycophenolic acid sodium additionally exhibits immunosuppressive, antiangiogenic, and antitumor activities. Mycophenolic acid sodium is widely utilized in virology, immunology, angiogenesis, and cancer biology research involving nucleotide biosynthesis regulation. |
| Targets & IC50 | IMPDH:0.24μM(EC50) |
| In vitro | Mycophenolic acid sodium has been demonstrated to possess antiviral properties against an array of RNA viruses, including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus [1]. Mycophenolic acid sodium (0.01-1 μM, 72 h) displays a selective inhibitory effect on the proliferation of endothelial cells and fibroblasts, with endothelial cells being more susceptible (IC 50 <500 nM) to its antimitotic effects [2]. In contrast, fibroblasts showed a higher tolerance (IC 50 <1 μM). Among human tumor cell lines tested, A549 non-small cell lung cancer and PC3 prostate cancer cells manifested moderate sensitivity (IC 50 >1 μM), whereas U87 glioblastoma cells were resistant to up to 1 μM of mycophenolic acid sodium treatment [2]. Mycophenolic acid sodium (0.05-2 μM, 18 h) up-regulates NDRG1 while exhibits a down-regulation of HDAC2 and MYC in a dose-dependent[2]. |
| In vivo | Mycophenolic acid sodium (120 mg/kg; oral gavage; b.i.d.) exhibits potent anti-tumor activity by altering the tumor microenvironment and significantly inhibiting U87 tumor growth in BALB/c nude mice [2]. Using an athymic 8-week-old, 20 g BALB/c nu/nu mouse model with a Mycophenolic acid-resistant U87 tumor, 120 mg/kg of MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) was administered orally twice daily. After 14 days post-tumor implantation, the MMF-treated group showed a 70% reduction in tumor growth compared to controls. Furthermore, MMF treatment significantly decreased microvessel density (by 44%) and pericyte coverage (by 78%), as indicated by CD31 and α-smooth muscle actin staining, respectively, suggesting impaired tumor vascularization and underscoring its efficacy against tumor proliferation [2]. |
| Synonyms | Mycophenolate sodium |
| Molecular Weight | 342.32 |
| Formula | C17H19NaO6 |
| Cas No. | 37415-62-6 |
| Smiles | CC1=C2C(C(OC2)=O)=C(C(C/C=C(C)/CCC([O-])=O)=C1OC)O.[Na+] |
| Storage | Keep away from moisture, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (233.7 mM), Sonication is recommended. DMSO: 140 mg/mL (408.97 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.